A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease
← catalyst calendarNCT06481306 · readout in 139 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
224estimated
Sites
32
Countries
Canada, France, Italy +2
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-07-17 | actual | When the study began enrolling |
| Primary completion | 2027-01-06 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-11-16 | estimated | The whole study's end, after follow-up |
| First posted | 2024-07-01 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Anemia, Sickle Cell
- Healthy Volunteers
Interventions
- Drug: BMS-986470
- Drug: Placebo
- Drug: Famotidine
- Drug: Pantoprazole
Primary outcomes
what the primary-completion date above is the date OFNumber of participants with adverse events (AEs)
measured Up to 26 months
Number of participants with serious adverse events (SAEs)
measured Up to 26 months
Number of participants with AEs meeting protocol-defined Dose Limiting Toxicity (DLT) criteria
measured Up to 26 months
Number of participants with AEs leading to discontinuation
measured Up to 26 months
Number of deaths
measured Up to 26 months
Proportion of participants achieving HbF ≥ 10%
measured Up to 28 days after last dose
Proportion of participants achieving HbF ≥ 20%
measured Up to 28 days after last dose
Proportion of participants achieving HbF ≥ 30%
measured Up to 28 days after last dose
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed